Entry Point Capital, LLC Agios Pharmaceuticals, Inc. Transaction History
Entry Point Capital, LLC
- $171 Million
- Q3 2024
Shares
2 transactions
Others Institutions Holding AGIO
# of Institutions
232Shares Held
58.1MCall Options Held
403KPut Options Held
469K-
Farallon Capital Management LLC San Francisco, CA5.66MShares$336 Million1.26% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.55MShares$329 Million0.0% of portfolio
-
Black Rock Inc. New York, NY4.86MShares$289 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V83.74MShares$222 Million2.8% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.83MShares$168 Million0.01% of portfolio
About AGIOS PHARMACEUTICALS, INC.
- Ticker AGIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,818,000
- Market Cap $3.26B
- Description
- Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and ...